Telemus Capital LLC cut its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 1.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 11,057 shares of the medical equipment provider’s stock after selling 174 shares during the period. Telemus Capital LLC’s holdings in Smith & Nephew SNATS were worth $385,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SNN. Northwestern Mutual Wealth Management Co. boosted its stake in Smith & Nephew SNATS by 0.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 3,408 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 17 shares in the last quarter. Greenleaf Trust purchased a new stake in Smith & Nephew SNATS during the second quarter worth approximately $207,000. Paloma Partners Management Co purchased a new stake in Smith & Nephew SNATS during the first quarter worth approximately $200,000. RMB Capital Management LLC purchased a new stake in Smith & Nephew SNATS during the first quarter worth approximately $219,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Smith & Nephew SNATS during the first quarter worth approximately $224,000. Institutional investors own 7.23% of the company’s stock.

Shares of Smith & Nephew SNATS, Inc. (NYSE SNN) opened at 35.12 on Monday. The firm has a market cap of $15.38 billion, a PE ratio of 17.88 and a beta of 0.76. The stock’s 50 day moving average price is $34.83 and its 200-day moving average price is $32.75. Smith & Nephew SNATS, Inc. has a 52-week low of $26.97 and a 52-week high of $35.85.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/07/telemus-capital-llc-has-385000-position-in-smith-nephew-snats-inc-nysesnn.html.

A number of research firms have recently commented on SNN. Zacks Investment Research upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research report on Wednesday, June 7th. BidaskClub upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Smith & Nephew SNATS currently has a consensus rating of “Hold” and a consensus price target of $38.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Institutional Ownership by Quarter for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.